will it cross $32 today, page-7

Sentiment is coming back in.
Lucas Beaumont of Lincoln Indicators has it as a strong conviction buy read below
"Its liver cancer treatment has low market penetration and significant growth ahead. SRX has been compounding dosage sales for this treatment at 20 per cent per annum, a growth rate we don’t see letting up as estimates of market share remain in the single digits. Volatility is the investor’s friend in this case, with the recent pullback providing a 23 per cent discount to our valuation, so the stock looks compelling at current levels. SRX was trading at $27.70 on June 21."